Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
Deep-dive into cost-effectiveness analyses derived from the Fracture Intervention Trial (FIT), examining cost per QALY for alendronate, payer-coverage dynamics, and the real-world value calculation for patients considering bisphosphonate therapy.
Read clinical reviewDeep-dive into the FIT extension (FLEX) and long-term follow-up data for alendronate, covering durability of fracture protection, rebound risk after discontinuation, and late-emerging safety signals.
Read clinical reviewA deep-dive into the Fracture Intervention Trial's primary and secondary endpoints for alendronate in postmenopausal osteoporosis, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of fracture reduction.
Read clinical reviewDeep-dive into the FIT trial's pre-specified and post-hoc subgroup analyses for alendronate, examining differential fracture reduction by age, baseline BMD, prior fracture status, BMI, and biomarkers.
Read clinical reviewA critical appraisal of the FIT trial for alendronate, examining enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest concerns.
Read clinical reviewA deep methodological analysis of the FIT trial (1998 JAMA), examining how randomization, blinding, endpoint definitions, and statistical choices shaped the 47% vertebral fracture reduction finding for alendronate.
Read clinical reviewA deep-dive into the Fracture Intervention Trial (FIT) of alendronate: methodology, real results, limitations, and what this foundational bisphosphonate trial means for prescribing decisions today.
Read clinical review